Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a …
KS Reisinger, SL Block, E Lazcano-Ponce… - The Pediatric …, 2007 - journals.lww.com
Objective: Administration of a quadrivalent HPV-6/11/16/18 vaccine to 16-to 26-year-old
women was highly effective in preventing HPV-6/11/16/18-related cervical/vulvar/vaginal …
women was highly effective in preventing HPV-6/11/16/18-related cervical/vulvar/vaginal …
Immunogenicity and safety of a 9-valent HPV vaccine
P Van Damme, SE Olsson, S Block… - …, 2015 - publications.aap.org
OBJECTIVES: Prophylactic vaccination of youngwomen aged 16 to 26 years with the 9-
valent (6/11/16/18/31/33/45/52/58) human papillomavirus (HPV) virus-like particle (9vHPV) …
valent (6/11/16/18/31/33/45/52/58) human papillomavirus (HPV) virus-like particle (9vHPV) …
Long-term study of a quadrivalent human papillomavirus vaccine
D Ferris, R Samakoses, SL Block… - …, 2014 - publications.aap.org
BACKGROUND: We present a long-term safety, immunogenicity, and effectiveness study of
a quadrivalent human papillomavirus (HPV4) vaccine. METHODS: Sexually naive boys and …
a quadrivalent human papillomavirus (HPV4) vaccine. METHODS: Sexually naive boys and …
A randomized, double-blind, phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil …
T Vesikari, N Brodszki, P van Damme… - The Pediatric …, 2015 - journals.lww.com
Background: A 9-valent human papillomavirus (9vHPV) vaccine has been developed to
prevent infections and diseases related to HPV 6/11/16/18 [as per the licensed quadrivalent …
prevent infections and diseases related to HPV 6/11/16/18 [as per the licensed quadrivalent …
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in …
SL Block, T Nolan, C Sattler, E Barr, KED Giacoletti… - …, 2006 - publications.aap.org
OBJECTIVE. Prophylactic vaccination of 16-to 23-year-old females with a quadrivalent
human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine has been shown to …
human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine has been shown to …
Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant
C Pedersen, T Petaja, G Strauss, HC Rumke… - Journal of Adolescent …, 2007 - Elsevier
PURPOSE: In female individuals 15–25-years of age, the AS04-containing human
papillomavirus (HPV)–16/18 vaccine is highly immunogenic and provides up to 100 …
papillomavirus (HPV)–16/18 vaccine is highly immunogenic and provides up to 100 …
4-valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents after 10 years
DG Ferris, R Samakoses, SL Block… - …, 2017 - publications.aap.org
OBJECTIVES: We describe the final 10-year data for the long-term follow-up study of the 4-
valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents …
valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents …
Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine
SL Block, DR Brown, A Chatterjee… - The Pediatric …, 2010 - journals.lww.com
Background: We describe the safety of the human papillomavirus (HPV)-6/11/16/18 vaccine
using updated clinical trial data (median follow-up time of 3.6 years) and summarize up to 3 …
using updated clinical trial data (median follow-up time of 3.6 years) and summarize up to 3 …
[HTML][HTML] Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after …
SE Olsson, JA Restrepo, JC Reina, P Pitisuttithum… - Papillomavirus …, 2020 - Elsevier
Background The nine-valent human papillomavirus (9vHPV) vaccine protects against
infection and disease related to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. The pivotal …
infection and disease related to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. The pivotal …
Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine
AR Giuliano, E Lazcano-Ponce, L Villa… - The Journal of …, 2007 - academic.oup.com
Abstract Background. The quadrivalent (types 6, 11, 16, and 18) human papillomavirus
(HPV) L1 virus-like-particle vaccine was 95%–100% effective in preventing cervical and …
(HPV) L1 virus-like-particle vaccine was 95%–100% effective in preventing cervical and …